Balchem Corp Stock Price, News & Analysis

Balchem Corporation (NASDAQ:BCPC) announced the acquisition of Kappa Bioscience AS for an enterprise value of NOK 3.175B (approximately USD 338M). Kappa specializes in vitamin K2, essential for bone and heart health. This acquisition enhances Balchem's portfolio in science-based nutrients, expected to be accretive to earnings per share in 2022. Kappa's projected 2022 revenue is approximately NOK 500M (USD 53M). The deal will strengthen Balchem's market presence in Europe and the U.S., while Kappa will benefit from Balchem's established distribution network.

Balchem Corporation (NASDAQ: BCPC) reported a strong first quarter of 2022, with net earnings of $28.9 million and record net sales of $228.9 million, up 23.3% from the previous year. Adjusted net earnings rose to $33.4 million, reflecting a 17.3% increase, with earnings per share reaching $1.03. All three business segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—experienced double-digit sales growth. Despite rising operational costs, the company maintained solid profit margins and plans to further enhance its sustainability efforts.

Balchem Corporation (BCPC) has announced a conference call on April 29, 2022, at 11:00 AM ET, to discuss first-quarter results. The financial results will be released earlier that day before the market opens. CEO Ted Harris and CFO Martin Bengtsson will host the call, which can be accessed via toll-free number 1-877-407-8289. A replay will be available after the call until May 13, 2022. Balchem operates three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, delivering solutions across various industries.

Balchem Corporation (NASDAQ: BCPC) reported a strong fourth quarter for 2021, achieving net earnings of $24.9 million, up 12.6% from $22.2 million in Q4 2020. Record net sales reached $213.1 million, reflecting a 17.9% increase year-over-year. For the full year, net earnings totaled $96.1 million, up 13.6% from 2020. The adjusted EBITDA for Q4 was $45.6 million, representing a 4.7% increase. The company's segments—Human Nutrition, Animal Nutrition, and Specialty Products—all recorded sales growth. A dividend of $0.64 per share signifies stable financial management.

Balchem Corporation (NASDAQ: BCPC) will host a conference call on February 18, 2022, at 11:00 AM ET to discuss its fourth-quarter results. The financial results will be published prior to the market opening on the same day. Interested parties can access the call by dialing toll-free 1-877-407-8289 or local 1-201-689-8341, five minutes before the start. A replay will be available after the call until March 4, 2022. Balchem operates in three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products, focusing on enhancing health and well-being through specialized ingredients.

Alithya Group (NASDAQ: ALYA) continues its partnership with Balchem Corporation (NASDAQ: BCPC) to implement Microsoft Dynamics 365 across multiple global locations. This initiative, ongoing since 2017, aims to consolidate Balchem's operations and enhance financial visibility. The implementation spans over 20 plants in four countries, transitioning from multiple ERP systems. Balchem, a leader in nutrition and health solutions, emphasizes the importance of this digital transformation for supporting growth and operational efficiency.

Cornell University's recent research indicates that doubling the recommended prenatal choline intake significantly enhances childhood cognitive performance. The study, published in The FASEB Journal, found that children whose mothers consumed over 930 mg of choline during pregnancy showed enduring cognitive benefits by age seven. This research supports earlier findings from 2018 that linked higher maternal choline intake to improved infant cognition. The implications of this study may influence public health policies and encourage prenatal vitamin manufacturers to increase choline levels in their products.